APCER Life Sciences

apcerls.com

APCER Life Sciences is committed to improving health in partnership with its clients. We bring together safety, medical, regulatory, and technology resources to ensure that patients receive the safest, most effective therapies possible.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

news image

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More

DTX PHARMA TO PRESENT AT THE CHARDAN VIRTUAL 4TH ANNUAL GENETIC MEDICINES EVENT

Prnewswire | September 29, 2020

news image

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and will participate in 1x1 meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th, 2020 at 4:45 pm EDT. "At DTx, we are focused on treating the genetic drivers of disease by applying our FALCON technology plat...

Read More

Pharma Tech

VEEVA DEVELOPMENT CLOUD SIMPLIFIES DRUG DEVELOPMENT IN THE INDUSTRY

Veeva Systems | May 21, 2021

news image

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory,...

Read More

Business Insights, PHARMACY MARKET

MINDMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH CATALENT FOR ITS PATENTED ZYDIS® FAST-DISSOLVE TECHNOLOGY FOR USE WITH MM-120

Businesswire | August 07, 2023

news image

Mind Medicine Inc a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Under the terms of the licensing agreement, Catalent has granted MindMed access to its ...

Read More
news image

KIMERA® LABS FILES FIRST FDA INVESTIGATIONAL NEW DRUG (IND) APPLICATION USING XOGLO® FOR TREATMENT OF ARDS SECONDARY TO COVID-19

Prnewswire | August 18, 2020

Kimera® Labs Inc, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes. Founded in 2012, Kimera® generated the first publicly available isolated exosome product and has treated over 35,000 thousand patients for a variety of investigatio...

Read More
news image

DTX PHARMA TO PRESENT AT THE CHARDAN VIRTUAL 4TH ANNUAL GENETIC MEDICINES EVENT

Prnewswire | September 29, 2020

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and will participate in 1x1 meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th, 2020 at 4:45 pm EDT. "At DTx, we are focused on treating the genetic drivers of disease by applying our FALCON technology plat...

Read More
news image

Pharma Tech

VEEVA DEVELOPMENT CLOUD SIMPLIFIES DRUG DEVELOPMENT IN THE INDUSTRY

Veeva Systems | May 21, 2021

A growing number of life sciences companies are adopting Veeva Development Cloud applications from Veeva Systems in an industrywide shift to streamline drug development. quite 650 companies use Veeva Development Cloud applications today, and quite 250 are leveraging multiple Veeva Vault applications across functional areas to enable and connect drug development and manufacturing teams. Veeva Development Cloud brings together suites of unified applications for clinical, regulatory,...

Read More
news image

Business Insights, PHARMACY MARKET

MINDMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH CATALENT FOR ITS PATENTED ZYDIS® FAST-DISSOLVE TECHNOLOGY FOR USE WITH MM-120

Businesswire | August 07, 2023

Mind Medicine Inc a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology. Under the terms of the licensing agreement, Catalent has granted MindMed access to its ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us